A 35-year-old man with persistent asthma on inhaled beclomethasone 250 µg twice daily and salbutamol as needed presents with complaints of waking up 3–4 nights per week due to asthma symptoms and experiencing daytime breathlessness during moderate exertion (climbing 2 flights of stairs). His peak expiratory flow is 75% of predicted. He has no history of smoking or occupational exposure. What is the most appropriate next step in his asthma management?

Explanation

## Asthma Control Assessment & Step-Up Therapy ### Classification of Asthma Control This patient has **inadequately controlled persistent asthma** based on: - Nighttime awakenings 3–4 nights/week (indicates poor control) - Daytime symptoms limiting activity (moderate exertion dyspnea) - PEF 75% of predicted (suboptimal) - Current therapy: ICS monotherapy at standard dose **Key Point:** Asthma control is assessed by **symptom frequency, activity limitation, and lung function**, not by asthma severity alone. A patient on low-dose ICS with inadequate control requires step-up therapy, not continuation of the same regimen. ### GINA Step-Up Algorithm for Inadequate Control | Current Step | Therapy | If Inadequate Control → | Next Step | |---|---|---|---| | Step 2: Low-dose ICS | ICS 100–250 µg daily | Nighttime symptoms, activity limitation | Step 3: ICS + LABA | | Step 3: ICS + LABA | ICS 250–500 µg + LABA | Persistent symptoms despite ICS + LABA | Step 4: Higher-dose ICS + LABA ± LTRA | | Step 4: High-dose ICS + LABA | ICS 500–1000 µg + LABA | Ongoing poor control | Step 5: Add oral corticosteroid or biologic | **High-Yield:** The **gold standard step-up from ICS monotherapy is ICS + LABA combination**, NOT increasing ICS dose alone. LABA addition provides superior control of nighttime symptoms and exacerbations compared to ICS dose escalation alone [cite:GINA 2023]. **Clinical Pearl:** LABA should NEVER be used as monotherapy — it must always be combined with an ICS. LABA monotherapy increases asthma-related mortality. **Mnemonic: STEP-UP (Asthma Control)** - **S**ymptoms (nighttime, daytime, activity limitation) - **T**herapy response (current regimen inadequate?) - **E**scalate to next GINA step - **P**refer ICS + LABA over ICS dose increase alone - **U**se combination inhalers for adherence - **P**eriodic reassessment (4–12 weeks post-step-up) ### Why ICS + LABA is Superior to ICS Dose Escalation 1. **Synergistic action** — LABA relaxes smooth muscle; ICS reduces inflammation 2. **Better nocturnal control** — LABA provides 12-hour bronchodilation 3. **Lower total ICS exposure** — combination at moderate doses better than high-dose ICS alone 4. **Reduced exacerbation rate** — LABA addition reduces exacerbations by ~20% vs. ICS dose increase [cite:Harrison 21e Ch 297; GINA 2023]